Prieur Marc sold $578K of ATR

Prieur Marc (Segment President) sold 5,000 shares of APTARGROUP, INC. (ATR) at an average of $115.58 ($115.53–$116.08, $0.58M total) across 2 trades on 2026-06-09.

Original reporting
SEC EDGAR · Prieur Marc
Published Jun 10, 2026, 7:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 7:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATR
Neutral
medium confidence
Mentioned
$ATR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this disclosure alone does not change company fundamentals.

02

Market read

A single officer open-market sale of ~$578K in ATR shares was newly disclosed via SEC Form 4.

03

What to watch

The article doesn’t state whether the sale was part of a broader planned program (10b5-1 is marked as no), nor does it provide context on total insider activity or option exercises.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-10 for a sale executed 2026-06-09

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for APTARGROUP, INC. (ATR).

Company-level read

Ticker impact

$ATRNeutralMedium confidence
Context

SEC Form 4 shows ATR insider Prieur Marc (Segment President) sold 5,000 shares for ~$577.9K on 2026-06-09 via open-market sale.

Expected impact

Low near-term impact; any reaction is likely muted unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a primary-source disclosure, but it is an open-market sale with no 10b5-1 plan stated and no accompanying fundamental news in the article.

Market effects

No sector-level read-through; this is a single-insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales are often pre-planned for diversification or tax; without evidence of distress, the signal may be noise.

Key entities

  • APTARGROUP, INC.

    Company whose insider transaction was reported on Form 4.

  • Prieur Marc

    Segment President who sold 5,000 shares of ATR on 2026-06-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.